Two classes of RAS blockers, i.e., angiotensin-converting enzyme (ACE) inhibitors (e.g., enalapril) and AT1 receptor antagonists (e.g., losartan), serve as first-line drugs for the treatment of essential hypertension according to the guidelines of American [3] and European [8] heart societies. The gene discussed is ACE; the disease is essential hypertension.